Dutch Delegation Promises ‘Seamless’ Transition To EMA’s New Home
Executive Summary
Dutch officials took part in the December meeting of the EMA management board and presented details of their plans for the agency’s relocation to Amsterdam. The board also adopted the 2018 work program and budget, which allow for a 6.8% rise in fee-related revenue next year, and said phase 2 of the Brexit business continuity plan would begin in January.
You may also be interested in...
Dutch Defend Choice Of Amsterdam For EMA As Italy Tries To Shift Agency To Milan
The Italian government has asked the Court of Justice of the EU to annul the decision to site the European Medicines Agency in Amsterdam and wants to move the agency instead to Milan. But the Dutch government insists that the selection process was “fair” and that the need for temporary premises had been made clear all along.
Industry Response To Brexit Survey Key For Future Planning, Says EMA
Sponsors of centrally authorized medicines in the EU are being urged to respond to a survey by the European Medicines Agency aimed at gauging industry's preparedness for Brexit. Companies have until Feb. 9 to complete survey, which the EMA says is critical to help with resource planning and ensuring a smooth transition.
EMA To Consult Staff On Relocation Plans Again As Brexit Time Pressure Mounts
The EMA is planning another survey to see how many of its staff are likely to follow it to Amsterdam, while the agency’s executive director says having to move into temporary premises while a permanent home is constructed is inconvenient but should allow core regulatory activities to be pursued.